These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
546 related articles for article (PubMed ID: 18359536)
1. VIP balances innate and adaptive immune responses induced by specific stimulation of TLR2 and TLR4. Arranz A; Juarranz Y; Leceta J; Gomariz RP; Martínez C Peptides; 2008 Jun; 29(6):948-56. PubMed ID: 18359536 [TBL] [Abstract][Full Text] [Related]
2. Effect of VIP on TLR2 and TLR4 expression in lymph node immune cells during TNBS-induced colitis. Arranz A; Abad C; Juarranz Y; Torroba M; Rosignoli F; Leceta J; Gomariz RP; Martínez C Ann N Y Acad Sci; 2006 Jul; 1070():129-34. PubMed ID: 16888154 [TBL] [Abstract][Full Text] [Related]
3. Time-course expression of Toll-like receptors 2 and 4 in inflammatory bowel disease and homeostatic effect of VIP. Gomariz RP; Arranz A; Abad C; Torroba M; Martinez C; Rosignoli F; Garcia-Gómez M; Leceta J; Juarranz Y J Leukoc Biol; 2005 Aug; 78(2):491-502. PubMed ID: 15857940 [TBL] [Abstract][Full Text] [Related]
4. Loss of Toll-like receptor 2 and 4 leads to differential induction of endoplasmic reticulum stress and proapoptotic responses in the intestinal epithelium under conditions of chronic inflammation. Messlik A; Schmechel S; Kisling S; Bereswill S; Heimesaat MM; Fischer A; Göbel U; Haller D J Proteome Res; 2009 Oct; 8(10):4406-17. PubMed ID: 19681597 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Abad C; Martinez C; Juarranz MG; Arranz A; Leceta J; Delgado M; Gomariz RP Gastroenterology; 2003 Apr; 124(4):961-71. PubMed ID: 12671893 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic treatment of experimental colitis with regulatory dendritic cells generated with vasoactive intestinal peptide. Gonzalez-Rey E; Delgado M Gastroenterology; 2006 Dec; 131(6):1799-811. PubMed ID: 17087944 [TBL] [Abstract][Full Text] [Related]
7. Synergism of toll-like receptor 2 (TLR2), TLR4, and TLR6 ligation on the production of tumor necrosis factor (TNF)-alpha in a spontaneous arthritis animal model of interleukin (IL)-1 receptor antagonist-deficient mice. Jung YO; Cho ML; Lee SY; Oh HJ; Park JS; Park MK; Park MJ; Ju JH; Kim SI; Park SH; Kim HY; Min JK Immunol Lett; 2009 Apr; 123(2):138-43. PubMed ID: 19428561 [TBL] [Abstract][Full Text] [Related]
8. Pivotal advance: vasoactive intestinal peptide inhibits up-regulation of human monocyte TLR2 and TLR4 by LPS and differentiation of monocytes to macrophages. Foster N; Lea SR; Preshaw PM; Taylor JJ J Leukoc Biol; 2007 Apr; 81(4):893-903. PubMed ID: 16973891 [TBL] [Abstract][Full Text] [Related]
9. VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblasts. Gutiérrez-Cañas I; Juarranz Y; Santiago B; Arranz A; Martinez C; Galindo M; Payá M; Gomariz RP; Pablos JL Rheumatology (Oxford); 2006 May; 45(5):527-32. PubMed ID: 16319097 [TBL] [Abstract][Full Text] [Related]
10. Toll-like receptor 2, 3, and 4 expression and function in human airway smooth muscle. Sukkar MB; Xie S; Khorasani NM; Kon OM; Stanbridge R; Issa R; Chung KF J Allergy Clin Immunol; 2006 Sep; 118(3):641-8. PubMed ID: 16950283 [TBL] [Abstract][Full Text] [Related]
11. Shift towards pro-inflammatory intestinal bacteria aggravates acute murine colitis via Toll-like receptors 2 and 4. Heimesaat MM; Fischer A; Siegmund B; Kupz A; Niebergall J; Fuchs D; Jahn HK; Freudenberg M; Loddenkemper C; Batra A; Lehr HA; Liesenfeld O; Blaut M; Göbel UB; Schumann RR; Bereswill S PLoS One; 2007 Jul; 2(7):e662. PubMed ID: 17653282 [TBL] [Abstract][Full Text] [Related]
12. AMPK agonist downregulates innate and adaptive immune responses in TNBS-induced murine acute and relapsing colitis. Bai A; Ma AG; Yong M; Weiss CR; Ma Y; Guan Q; Bernstein CN; Peng Z Biochem Pharmacol; 2010 Dec; 80(11):1708-17. PubMed ID: 20797389 [TBL] [Abstract][Full Text] [Related]
13. Interleukin-11 reduces TLR4-induced colitis in TLR2-deficient mice and restores intestinal STAT3 signaling. Gibson DL; Montero M; Ropeleski MJ; Bergstrom KS; Ma C; Ghosh S; Merkens H; Huang J; Månsson LE; Sham HP; McNagny KM; Vallance BA Gastroenterology; 2010 Oct; 139(4):1277-88. PubMed ID: 20600022 [TBL] [Abstract][Full Text] [Related]
15. Toll-like receptor 2 and 4 combination engagement upregulate IL-15 synergistically in human rheumatoid synovial fibroblasts. Jung YO; Cho ML; Kang CM; Jhun JY; Park JS; Oh HJ; Min JK; Park SH; Kim HY Immunol Lett; 2007 Mar; 109(1):21-7. PubMed ID: 17289161 [TBL] [Abstract][Full Text] [Related]
16. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease. Lee J; Lee EN; Kim EY; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Lee KW; Kwon GY; Joh JW; Kim SJ Immunol Lett; 2005 Nov; 101(2):210-6. PubMed ID: 16026855 [TBL] [Abstract][Full Text] [Related]
17. Hypertonic saline enhances host defense to bacterial challenge by augmenting Toll-like receptors. Chen LW; Huang HL; Lee IT; Hsu CM; Lu PJ Crit Care Med; 2006 Jun; 34(6):1758-68. PubMed ID: 16625117 [TBL] [Abstract][Full Text] [Related]
18. Hyperthermia differentially regulates TLR4 and TLR2-mediated innate immune response. Zhao W; An H; Zhou J; Xu H; Yu Y; Cao X Immunol Lett; 2007 Feb; 108(2):137-42. PubMed ID: 17196259 [TBL] [Abstract][Full Text] [Related]
19. A transient breach in the epithelial barrier leads to regulatory T-cell generation and resistance to experimental colitis. Boirivant M; Amendola A; Butera A; Sanchez M; Xu L; Marinaro M; Kitani A; Di Giacinto C; Strober W; Fuss IJ Gastroenterology; 2008 Nov; 135(5):1612-1623.e5. PubMed ID: 18765239 [TBL] [Abstract][Full Text] [Related]
20. Polyamines are required for expression of Toll-like receptor 2 modulating intestinal epithelial barrier integrity. Chen J; Rao JN; Zou T; Liu L; Marasa BS; Xiao L; Zeng X; Turner DJ; Wang JY Am J Physiol Gastrointest Liver Physiol; 2007 Sep; 293(3):G568-76. PubMed ID: 17600044 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]